A –Sima Sistani: Hey, Alex. It’s Sima. I think that’s our key differentiator with the platform is that right now on top of supply constraints, insurance makes it hard for many to access the medication and we see about a 30% to 35% approval of prior authorizations through our Clinical business, which is better than the average, the range of estimated insurance coverage on these meds is somewhere between 20% to 25% and that is a result of the insurance engine that we have here where it makes it better able to actually increase the likelihood of coverage because so many mistakes are made in this process just due to errors that are clerical errors that can result in denials and just better system support in addition to the wide formulary.So we can file several PAs at the same time on multiple medications to help increase again the likelihood of coverage and then once we do help them with the preauthorization, we go into the part of the flow, which is around that med management and there’s a whole infrastructure there to support people with finding supply and it gets smart about which pharmacy actually has the supply and is able to benefit our population to have a better experience, frankly, while they’re on the platform, but that’s also why we have been very hesitant to market the service right now.We want to ensure that we retain the high NPS and the ability to get people the benefit that they’re seeking when they come for the Clinical option and so we’re looking forward to the hopeful eventual approval of tirzepatidefor obesity and then the ability to start marketing more aggressively.
Alex Fuhrman: Okay that’s really helpful. Thank you very much.
Operator: The next question comes from Michael Lasser from UBS.
Henry Carr: Hi. This is Henry Carr on. Good evening for Michael Lasser. I just wanted to start off with the Sequence question. So you have 27,000 subs in Aprilat the time of acquisition and you’ve increased it about to 8000 to 10,000 per quarter.How should we think about this rate of about 8000 to 10,000 subscribers per quarter going forward? So basically once supply conditions improve, how do you expect this rate increasing? Can you speak a little bit more about that?
Alex Fuhrman: Henry, thanks for your question. At this time, we’re not guiding into 2024. So I would say we’ve been conservative in our approach to the balance of the year, understanding the environment that we’re in with the supply constraints.So we’ve taken that thinking through the balance of this year.
Henry Carr: Okay. Thank you. And I just want to ask about student loan payments and how much of your subscriber base is potentially exposed to that?
A –Sima Sistani: Yeah, I don’t that’s not something that we have really observed, especially since, the majority of our population is between ages of 35 and 45 and so it’s not something that is, we have noticed to be relevant to our business.
Henry Carr: Great, thanks so much.
Operator: There are no more questions in the queue.This concludes our question and answer session. I would like to turn the conference back over to Sima Sistani for any closing remarks.
A –Sima Sistani: I just want to reiterate that I’m really encouraged by our performance and the momentum in our business and we are returning the company to the first year-over-year member sign up growth and now subscriber growth and accomplishing this again on less marketing spend year-to-date was no small achievements, but one that demonstrates making the right decisions to return Weight Watchers to profitable growth and prioritizing the long term health the business.We really look forward to speaking with many of you at upcoming conferences and events, including the Jefferies London Healthcare Conference on November 16th and at the Bank of America Leveraged Finance Conference later this month.Thanks again for joining us.
Operator: Conference has now concluded. Thank you for attending today’s presentation. You may now disconnect.
